What is Vita Life Sciences Limited's (VLS.AX) StockRank?

MoatMap's StockRank for Vita Life Sciences Limited (VLS.AX) is 100/100, with a Strong Buy signal. This is a composite score combining Quality (86), Value (75), and Momentum (77) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Vita Life Sciences Limited have an economic moat?

Vita Life Sciences Limited (VLS.AX) has a Quality factor score of 86/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Vita Life Sciences Limited a buy, hold, or sell?

MoatMap's current signal for Vita Life Sciences Limited (VLS.AX) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Vita Life Sciences Limited in?

Vita Life Sciences Limited (VLS.AX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VLS.AX

Strong BuyFull HouseFLAG

Vita Life Sciences Limited · Healthcare · Australia · $109M · Avg Vol: $30K/d

100

StockRank

Get insider-trade alerts

P/E (TTM)

13.9x

ROE

20.6%

D/E

0.0x

Dividend %

5.2%

AI CONVICTION THESIS

While Vita Life Sciences shows consistent buyback activity, the valuation and scale limit the asymmetric potential required for high conviction. The business is a steady compounder, but current macro conditions do not provide the explosive thematic velocity required to qualify as a top-tier holding for a concentrated book.

COMPANY DESCRIPTION

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods.

FINANCIAL SUMMARY (AUD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	66.9M	74.2M	79.5M	93.3M	11.7%	96.5M
EPS (AUD)	0.13	0.17	0.16	0.19	11.7%	0.20
Shares	53.0M	56.4M	56.6M	55.5M	+4.8%	54.4M
Debt	0.6M	0.4M	0.5M	2.4M	58.5%	2.2M
Equity	36.6M	43.4M	52.4M	56.3M	15.4%	—
Op CF	2.8M	13.0M	6.2M	16.4M	80.9%	14.9M
Inv CF	-0.1M	-0.7M	-0.2M	-0.6M	—	—
Fin CF	-3.1M	-2.9M	-3.0M	-9.1M	—	—

Loading 1Y...

PRICE (1Y)+13.1%

SMA 50SMA 200

$1.97

RSI (14)

38.5

52W High

$2.00

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

25.4%94.5

ROE

20.6%89.1

GP/Assets

73.2%95.1

Op. Margin

15.8%76.4

FCF/Assets

15.2%93.7

Piotroski

783.9

Int. Cover

41.9x77.3

D/E Ratio

0.04x73.8

Current Ratio

2.82x52.7

Value

P/E (TTM)

13.9x76.9

EV/EBITDA

7.9x79.9

P/FCF

12.1x79.5

P/B

2.8x49.7

P/S

1.6x74.2

Div Yield

5.2%90.9

Momentum

52W High %

99%99.0

RS 6M

9%74.2

SMA 50/200

1.03x64.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

15%50.6

FUNDAMENTALS

Market Cap

$109M

P/E (Forward)

—

Gross Margin

62.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VLS.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
VLS.AX	Vita Life Sciences Limited(you)	$109M	100	Strong Buy
BLS.AX	BLS Pharmaceuticals Limited	$152M	82	Strong Buy
AHC.AX	Austco Healthcare Limited	$66M	85	Strong Buy
ACL.AX	Australian Clinical Labs Limited	$374M	99	Strong Buy
CUV.AX	Clinuvel Pharmaceuticals Limited	$306M	91	Strong Buy
CGS.AX	Cogstate Limited	$380M	86	Strong Buy
ALC.AX	Alcidion Group Limited	$93M	62	Hold
MVF.AX	Monash IVF Group Limited	$190M	66	Buy
MYX.AX	Mayne Pharma Group Limited	$175M	61	Hold
PGC.AX	Paragon Care Limited	$163M	58	Hold

Peer medians: ROE -25.5% · P/E 36.4x · Gross margin 61.2%

Vita Life Sciences Limited (VLS.AX): Stock Score Summary

Vita Life Sciences Limited (VLS.AX) has a MoatMap StockRank of 100/100 based on Quality (86/100), Value (75/100), and Momentum (77/100) factor scores. The current signal is STRONG BUY. While Vita Life Sciences shows consistent buyback activity, the valuation and scale limit the asymmetric potential required for high conviction. The business is a steady compounder, but current macro conditions do not provide the explosive thematic velocity required to qualify as a top-tier holding for a concentrated book.

Key Financial Metrics

Price	$1.97
Market Cap	$109M
P/E (TTM)	13.95
Price/Book	2.75
Return on Equity	20.6%
Return on Invested Capital	25.4%
Debt/Equity	0.04x
Gross Margin	62.8%
Operating Margin	15.8%
Revenue Growth	6.1%
Dividend Yield	5.2%
Free Cash Flow	$9M

Vita Life Sciences Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Vita Life Sciences Limited’s (VLS.AX) StockRank?: MoatMap’s StockRank for Vita Life Sciences Limited (VLS.AX) is 100/100, with a Strong Buy signal. It is a composite of Quality (86), Value (75), and Momentum (77) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Vita Life Sciences Limited have an economic moat?: Vita Life Sciences Limited (VLS.AX) has a Quality factor score of 86/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vita Life Sciences Limited a buy, hold, or sell?: MoatMap’s current signal for Vita Life Sciences Limited (VLS.AX) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Vita Life Sciences Limited in?: Vita Life Sciences Limited (VLS.AX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Australia).